{"id":4867,"date":"2023-12-19T17:33:09","date_gmt":"2023-12-19T16:33:09","guid":{"rendered":"https:\/\/www.asimas.it\/new_asimas\/?p=4867"},"modified":"2023-12-19T17:42:02","modified_gmt":"2023-12-19T16:42:02","slug":"ayvakyt-avapritinib-approvato-dalla-commissione-europea","status":"publish","type":"post","link":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/","title":{"rendered":"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p>Ciao mondo Asimas!<\/p>\n<p>&nbsp;<\/p>\n<p>La Blueprint Medicines Corporation ha annunciato pochi giorni fa che la Commissione Europea ha approvato il farmaco AYVAKYT (AVAPRITINIB) per il trattamento di pazienti adulti affetti da mastocitosi sistemica indolente con sintomi da moderati a gravi non adeguatamente controllati dal trattamento sintomatico.<\/p>\n<p>Nell&#8217;Unione Europea i pazienti affetti da mastocitosi sistemica indolente dispongono ora di un farmaco approvato che tratta la causa principale della malattia.<\/p>\n<p>Approvazione basata sui dati dello studio PIONEER ha ottenuto miglioramenti significativi in un&#8217;ampia gamma di sintomi con un profilo di sicurezza molto alto.<\/p>\n<p>&nbsp;<\/p>\n<p>Ecco allora di seguito la documentazione ufficiale:<\/p>\n<div class=\"x1e56ztr\">\n<p><a href=\"http:\/\/www.asimas.it\/new_asimas\/wp-content\/uploads\/2023\/12\/Comunicato_stampa_AYVAKYT.pdf\" target=\"_blank\" rel=\"noopener\">Clicca qui per leggere la versione originale tradotta in italiano &gt;&gt;<\/a><\/p>\n<p><a href=\"https:\/\/www.blueprintmedicines.com\/wp-content\/uploads\/2023\/12\/Blueprint-Medicines-EC-Approval-ISM.pdf?fbclid=IwAR2mlr33QaL7Kg9zqmHDJsH47AwFKq4NIS2a6njzOHHiMXIbPDouKn9WlyQ\" target=\"_blank\" rel=\"noopener\">Clicca qui per leggere la versione originale &gt;&gt;<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>Una bellisima notizia per tutti noi <span class=\"x3nfvp2 x1j61x8r x1fcty0u xdj266r xhhsvwb xat24cr xgzva0m xxymvpz xlup9mm x1kky2od\"><img loading=\"lazy\" class=\"xz74otr\" src=\"https:\/\/static.xx.fbcdn.net\/images\/emoji.php\/v9\/t1e\/2\/16\/1f60a.png\" alt=\"\ud83d\ude0a\" width=\"16\" height=\"16\"><\/span>&nbsp;sempre meno soli e sempre pi\u00f9 fiduciosi!&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>Un abbraccio,<\/p>\n<p>Asimas &#8211; Associazione Italiana Mastocitosi<\/p>\n<p>&nbsp;<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Ciao mondo Asimas! &nbsp; La Blueprint Medicines Corporation ha annunciato pochi giorni fa che la Commissione Europea ha approvato il farmaco AYVAKYT (AVAPRITINIB) per il trattamento di pazienti adulti [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[20,2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v18.4.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\r\n<title>AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea - Asimas<\/title>\r\n<meta name=\"robots\" content=\"noindex, follow\" \/>\r\n<meta property=\"og:locale\" content=\"it_IT\" \/>\r\n<meta property=\"og:type\" content=\"article\" \/>\r\n<meta property=\"og:title\" content=\"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea - Asimas\" \/>\r\n<meta property=\"og:description\" content=\"&nbsp; Ciao mondo Asimas! &nbsp; La Blueprint Medicines Corporation ha annunciato pochi giorni fa che la Commissione Europea ha approvato il farmaco AYVAKYT (AVAPRITINIB) per il trattamento di pazienti adulti [&hellip;]\" \/>\r\n<meta property=\"og:url\" content=\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/\" \/>\r\n<meta property=\"og:site_name\" content=\"Asimas\" \/>\r\n<meta property=\"article:published_time\" content=\"2023-12-19T16:33:09+00:00\" \/>\r\n<meta property=\"article:modified_time\" content=\"2023-12-19T16:42:02+00:00\" \/>\r\n<meta property=\"og:image\" content=\"https:\/\/static.xx.fbcdn.net\/images\/emoji.php\/v9\/t1e\/2\/16\/1f60a.png\" \/>\r\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\r\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"Dani\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\r\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/#organization\",\"name\":\"ASIMAS - Associazione Italiana Mastocitosi\",\"url\":\"https:\/\/www.asimas.it\/new_asimas\/\",\"sameAs\":[],\"logo\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/#logo\",\"inLanguage\":\"it-IT\",\"url\":\"https:\/\/www.asimas.it\/new_asimas\/wp-content\/uploads\/2019\/04\/logo-asimas.png\",\"contentUrl\":\"https:\/\/www.asimas.it\/new_asimas\/wp-content\/uploads\/2019\/04\/logo-asimas.png\",\"width\":240,\"height\":240,\"caption\":\"ASIMAS - Associazione Italiana Mastocitosi\"},\"image\":{\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/#logo\"}},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/#website\",\"url\":\"https:\/\/www.asimas.it\/new_asimas\/\",\"name\":\"Asimas\",\"description\":\"Associazione Italiana Mastocitosi\",\"publisher\":{\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.asimas.it\/new_asimas\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"it-IT\"},{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#primaryimage\",\"inLanguage\":\"it-IT\",\"url\":\"https:\/\/static.xx.fbcdn.net\/images\/emoji.php\/v9\/t1e\/2\/16\/1f60a.png\",\"contentUrl\":\"https:\/\/static.xx.fbcdn.net\/images\/emoji.php\/v9\/t1e\/2\/16\/1f60a.png\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#webpage\",\"url\":\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/\",\"name\":\"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea - Asimas\",\"isPartOf\":{\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#primaryimage\"},\"datePublished\":\"2023-12-19T16:33:09+00:00\",\"dateModified\":\"2023-12-19T16:42:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.asimas.it\/new_asimas\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea\"}]},{\"@type\":\"Article\",\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#webpage\"},\"author\":{\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/#\/schema\/person\/f4cff0d0946e80b069d013531ab38b84\"},\"headline\":\"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea\",\"datePublished\":\"2023-12-19T16:33:09+00:00\",\"dateModified\":\"2023-12-19T16:42:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#webpage\"},\"wordCount\":152,\"publisher\":{\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/static.xx.fbcdn.net\/images\/emoji.php\/v9\/t1e\/2\/16\/1f60a.png\",\"articleSection\":[\"2023\",\"News\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/#\/schema\/person\/f4cff0d0946e80b069d013531ab38b84\",\"name\":\"Dani\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\/\/www.asimas.it\/new_asimas\/#personlogo\",\"inLanguage\":\"it-IT\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c03fe6a88949b182e89f15f862f46000?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c03fe6a88949b182e89f15f862f46000?s=96&d=mm&r=g\",\"caption\":\"Dani\"},\"url\":\"https:\/\/www.asimas.it\/new_asimas\/author\/admin\/\"}]}<\/script>\r\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea - Asimas","robots":{"index":"noindex","follow":"follow"},"og_locale":"it_IT","og_type":"article","og_title":"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea - Asimas","og_description":"&nbsp; Ciao mondo Asimas! &nbsp; La Blueprint Medicines Corporation ha annunciato pochi giorni fa che la Commissione Europea ha approvato il farmaco AYVAKYT (AVAPRITINIB) per il trattamento di pazienti adulti [&hellip;]","og_url":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/","og_site_name":"Asimas","article_published_time":"2023-12-19T16:33:09+00:00","article_modified_time":"2023-12-19T16:42:02+00:00","og_image":[{"url":"https:\/\/static.xx.fbcdn.net\/images\/emoji.php\/v9\/t1e\/2\/16\/1f60a.png"}],"twitter_card":"summary_large_image","twitter_misc":{"Scritto da":"Dani","Tempo di lettura stimato":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Organization","@id":"https:\/\/www.asimas.it\/new_asimas\/#organization","name":"ASIMAS - Associazione Italiana Mastocitosi","url":"https:\/\/www.asimas.it\/new_asimas\/","sameAs":[],"logo":{"@type":"ImageObject","@id":"https:\/\/www.asimas.it\/new_asimas\/#logo","inLanguage":"it-IT","url":"https:\/\/www.asimas.it\/new_asimas\/wp-content\/uploads\/2019\/04\/logo-asimas.png","contentUrl":"https:\/\/www.asimas.it\/new_asimas\/wp-content\/uploads\/2019\/04\/logo-asimas.png","width":240,"height":240,"caption":"ASIMAS - Associazione Italiana Mastocitosi"},"image":{"@id":"https:\/\/www.asimas.it\/new_asimas\/#logo"}},{"@type":"WebSite","@id":"https:\/\/www.asimas.it\/new_asimas\/#website","url":"https:\/\/www.asimas.it\/new_asimas\/","name":"Asimas","description":"Associazione Italiana Mastocitosi","publisher":{"@id":"https:\/\/www.asimas.it\/new_asimas\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.asimas.it\/new_asimas\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"it-IT"},{"@type":"ImageObject","@id":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#primaryimage","inLanguage":"it-IT","url":"https:\/\/static.xx.fbcdn.net\/images\/emoji.php\/v9\/t1e\/2\/16\/1f60a.png","contentUrl":"https:\/\/static.xx.fbcdn.net\/images\/emoji.php\/v9\/t1e\/2\/16\/1f60a.png"},{"@type":"WebPage","@id":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#webpage","url":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/","name":"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea - Asimas","isPartOf":{"@id":"https:\/\/www.asimas.it\/new_asimas\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#primaryimage"},"datePublished":"2023-12-19T16:33:09+00:00","dateModified":"2023-12-19T16:42:02+00:00","breadcrumb":{"@id":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.asimas.it\/new_asimas\/"},{"@type":"ListItem","position":2,"name":"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea"}]},{"@type":"Article","@id":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#article","isPartOf":{"@id":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#webpage"},"author":{"@id":"https:\/\/www.asimas.it\/new_asimas\/#\/schema\/person\/f4cff0d0946e80b069d013531ab38b84"},"headline":"AYVAKYT (AVAPRITINIB) approvato dalla Commissione Europea","datePublished":"2023-12-19T16:33:09+00:00","dateModified":"2023-12-19T16:42:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#webpage"},"wordCount":152,"publisher":{"@id":"https:\/\/www.asimas.it\/new_asimas\/#organization"},"image":{"@id":"https:\/\/www.asimas.it\/new_asimas\/ayvakyt-avapritinib-approvato-dalla-commissione-europea\/#primaryimage"},"thumbnailUrl":"https:\/\/static.xx.fbcdn.net\/images\/emoji.php\/v9\/t1e\/2\/16\/1f60a.png","articleSection":["2023","News"],"inLanguage":"it-IT"},{"@type":"Person","@id":"https:\/\/www.asimas.it\/new_asimas\/#\/schema\/person\/f4cff0d0946e80b069d013531ab38b84","name":"Dani","image":{"@type":"ImageObject","@id":"https:\/\/www.asimas.it\/new_asimas\/#personlogo","inLanguage":"it-IT","url":"https:\/\/secure.gravatar.com\/avatar\/c03fe6a88949b182e89f15f862f46000?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c03fe6a88949b182e89f15f862f46000?s=96&d=mm&r=g","caption":"Dani"},"url":"https:\/\/www.asimas.it\/new_asimas\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.asimas.it\/new_asimas\/wp-json\/wp\/v2\/posts\/4867"}],"collection":[{"href":"https:\/\/www.asimas.it\/new_asimas\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.asimas.it\/new_asimas\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.asimas.it\/new_asimas\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.asimas.it\/new_asimas\/wp-json\/wp\/v2\/comments?post=4867"}],"version-history":[{"count":18,"href":"https:\/\/www.asimas.it\/new_asimas\/wp-json\/wp\/v2\/posts\/4867\/revisions"}],"predecessor-version":[{"id":4891,"href":"https:\/\/www.asimas.it\/new_asimas\/wp-json\/wp\/v2\/posts\/4867\/revisions\/4891"}],"wp:attachment":[{"href":"https:\/\/www.asimas.it\/new_asimas\/wp-json\/wp\/v2\/media?parent=4867"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.asimas.it\/new_asimas\/wp-json\/wp\/v2\/categories?post=4867"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.asimas.it\/new_asimas\/wp-json\/wp\/v2\/tags?post=4867"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}